ArticleCell communication and signaling : CCS2022

RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis.

Zhongbo Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.